Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of IoGen™ for the Treatment of Moderate or Severe, Periodic Breast Pain Associated With Symptomatic Fibrocystic Breast Disease

NCT00237523 is registered in ClinicalTrials.gov with Symbollon Pharmaceuticals as lead sponsor.

NCT NCT00237523
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00237523 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of IoGen™ for the Treatment of Moderate or Severe, Periodic Breast Pain Associated With Symptomatic Fibrocystic Breast Disease
Lead sponsor
Symbollon Pharmaceuticals
Phase
Phase 3
Overall status
Unknown status
Start date
July 31, 2005
Completion date
March 31, 2008
Enrollment
175 (estimated)
Sites
39

Conditions

As the registry lists them; a condition with its own page is linked.

fibrocystic changes of breast, fibrocystic disease of breast, fibrocystic mastopathy, pain